Table 5.

Model-based Relationship (B) between Medication Class and Driving Outcomes, Adjusted for Covariates^a

	Speeding		Rapid Deceleration		Right-to-Left Turn Ratio
Medication Class	B	p-value	B	p-value	B	p-value
Antihistamine	−.018	.790	−.010	.779	.016	.016
Anti-infective agents	.059	.424	−.027	.515	−.012	.096
Anti-neoplastic agents	.221	.054	.058	.376	.008	.469
Autonomic	.024	.670	.052	.099	.005	.394
Blood Formation, Coagulation	−.079	.242	.021	.586	−.003	.674
Cardiovascular	−.031	.561	−.055	.068	−.004	.487
CNS agents	.143	.004	.040	.165	.040	.165
Electrolytic	−.078	.105	−.110	<.001	.000	.933
EENT	−.075	.164	.046	.139	.003	.583
Gastrointestinal drugs	.058	.242	.061	.032	.006	.219
Hormones and synthetic substitutes	.054	.252	.060	.024	.003	.562
Local anesthetics	−.002	.993	.133	.350	.001	.966
Skin and mucous membrane agents	−.005	.936	.029	.423	−.005	.454
Smooth Muscle Relaxants	.007	.957	−.020	.779	−.002	.893
Vitamins	−.021	.675	−.034	.228	−.010	.053

^aCovariates: total number of medications, miles driven per year, total days driving, sex, age, race/ethnicity, education, urban/rural residence, income, employment, study site